Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review
What this study found
Resveratrol showed modest metabolic benefits overall, with significant reductions in waist circumference, HbA1c, total cholesterol, and LDL-C, and a reported improvement in HDL-C. Key pooled effects were WC SMD -0.36 (95% CI -0.59 to -0.14; P = 0.002), HbA1c SMD -0.48 (95% CI -0.69 to -0.27; P ≤ 0.001), TC SMD -0.15 (95% CI -0.30 to -0.01; P = 0.003), and LDL-C SMD -0.42 (95% CI -0.57 to -0.27; P ≤ 0.001). No significant effects were seen for body weight, BMI, fasting glucose, insulin, HOMA index, fat percentage, triglycerides, adiponectin, or leptin. The authors concluded that resveratrol…
- Study & population
- This systematic review and meta-analysis pooled 25 randomized controlled trials, including 21 parallel-group and 4 crossover studies.
- Intervention
- Oral resveratrol supplementation was tested against placebo in randomized trials.
- Key limitation
- Interpretation is limited by substantial between-study heterogeneity across many outcomes, with I2 values often very high (for example, 88% to 94% for some key endpoints).
View source
Open PDFOriginal abstract
Background Lipids are ubiquitous metabolites with diverse functions. Excessive lipid accumulation can trigger lipid redistribution among metabolic organs such as adipose, liver and muscle, thus altering the lipid metabolism. It has been revealed that disturbed lipid metabolism would cause multiple disease complications and is highly correlated with human morbidity. Resveratrol (RSV), a phytoestrogen with antioxidant, can modulate insulin resistance and lipid profile. Recently, research on RSV supplementation to improve glucose and lipid metabolism has been controversial. A meta-analysis may provide a scientific reference for the relationship between lipid metabolism and RSV supplementation. Methods and Analysis We searched the PubMed, Cochrane Library, Web of Science, and Embase databases from inception to October 2021 using relevant keywords. A comprehensive search for randomized controlled trials (RCTs) was performed. For calculating pooled effects, continuous data were pooled by mean difference (MD) and 95% confidence interval (CI). Adopting the method of inverse-variance with a random-effect, all related statistical analyses were performed using the Rev Man V.5.3 and STATA V.15 software. Results A total of 25 articles were incorporated into the final meta-analysis after removal of duplicates by checking titles and abstracts and excluding non-relevant articles. The selected articles had a total of 1,171 participants, including 578 in the placebo group and 593 in the intervention group. According to the current meta-analysis, which demonstrated that there was a significant decrease in waist circumference (SMD = –0.36; 95% CI: –0.59, –0.14; P = 0.002; I2 = 88%), hemoglobin A1c (–0.48; –0.69, –0.27; P ≤ 0.001; I2 = 94%), total cholesterol (–0.15; –0.3, –0.01; P = 0.003; I2 = 94%), low density lipoprotein cholesterol (–0.42; –0.57, –0.27; P ≤ 0.001; I2 = 92%), high density lipoprotein cholesterol (0.16; –0.31, –0.02; P = 0.03; I2 = 81%) following resveratrol administration. Conclusion These results suggest that RSV has a dramatic impact on regulating lipid and glucose metabolism, and the major clinical value of resveratrol intake is for obese and diabetic patients. We hope that this study could provide more options for clinicians using RSV. Furthermore, in the future, large-scale and well-designed trials will be warranted to confirm these results. Systematic Review Registration Website [https://www.crd.york.ac.uk/prospero/#recordDetails], identifier [CRD42021244904].